ALPHARMA AND SYNTHON PHARMACEUTICALS ANNOUNCE CO-PROMOTION AGREEMENT

Alpharma and Synthon Pharmaceuticals have announced that Alpharma's sales force will co-promote Synthon's Pexeva. Pexeva is a branded selective serotonin reuptake inhibitor for the treatment of depression, obsessive/compulsive disorder, and/or panic disorder. Pexeva was launched by Synthon in February 2004, and is supported by a specialist sales force focusing on psychiatry. Alpharma will promote this product along with its current branded product Kadian.

Yahoo News (http://biz.yahoo.com/prnews/050113/nyth078_2.html)